Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3161390
Author(s) Matter-Walstra, Klazien; Klingbiel, Dirk; Szucs, Thomas; Pestalozzi, Bernhard C.; Schwenkglenks, Matthias
Author(s) at UniBasel Matter-Walstra, Klazien
Schwenkglenks, Matthias
Szucs, Thomas
Year 2014
Title Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
Journal PharmacoEconomics
Volume 32
Number 6
Pages / Article-Number 591-599
Abstract

BACKGROUND: The European Quality of Life-5 Dimensions (EQ-5D) instrument combines questionnaire responses into a single utility estimate using country-specific value sets. Countries without a national value set are advised to select one based on geographic proximity. In the absence of a Swiss value set, we used foreign value sets to gain insights into their appropriateness for use with Swiss cancer patients. METHODS: EQ-5D health states and visual analogue scale (VAS) ratings were collected in one German and three Swiss oncology trials. Utilities were calculated based on the United Kingdom (UK), German (GE), French (FR) and European Union (EU) value sets. Resulting differences and Pearson partial correlation coefficients with corresponding VAS ratings were assessed. RESULTS: In total, 202 Swiss and 154 German patients undergoing cancer treatment completed at least two EQ-5D forms. The mean difference between GE-based and FR-, UK- or EU-based utilities was significantly larger than the differences between the latter. The absolute mean difference between utilities and VAS ratings was highest for GE-based utilities, for Swiss (0.170, 95 % confidence interval [CI] 0.146-0.194) and German patients (0.174, 95 % CI 0.145-0.202). The correlation between GE-based utilities and VAS ratings was the lowest (r = 0.36, 95 % CI 0.33-0.40); the highest was between FR-based utilities and VAS ratings (r = 0.43, 95 % CI 0.39-0.46). CONCLUSION: For Switzerland, utility calculations based on the German or French value set would be an obvious choice. Our results suggest that the German value set may not be the most appropriate for use with Swiss cancer patients. The French and EU value sets may be relevant alternatives and improve international comparability.

Publisher Adis International
ISSN/ISBN 1170-7690
URL http://www.ncbi.nlm.nih.gov/pubmed/24671924; http://link.springer.com/article/10.1007%2Fs40273-014-0151-0
edoc-URL http://edoc.unibas.ch/dok/A6411108
Full Text on edoc No
Digital Object Identifier DOI 10.1007/s40273-014-0151-0
ISI-Number WOS:000344625200007
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.348 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
13/05/2024